Device Endocrinology

T:Slim X2 Insulin Pump With Control-Iq

Payments companies reported to CMS as associated with T:Slim X2 Insulin Pump With Control-Iq. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.4Massociated payments (2023-2025)
7,734clinicians with associated payments
1company reporting

By year

2023 $222K
2024 $469K
2025 $719K

Payments reported as associated with T:Slim X2 Insulin Pump With Control-Iq, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Endocrinology, Diabetes & Metabolism $486K
Family $219K
Nurse Practitioner $189K
Physician Assistant $86K
Pediatric Endocrinology $84K
Internal Medicine $56K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with T:Slim X2 Insulin Pump With Control-Iq

These are the largest totals companies reported as associated with T:Slim X2 Insulin Pump With Control-Iq. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Mary Jane Mcdevitt Springfield, PA Nurse Practitioner $44,480.34
Mahnaz Mellati Seattle, WA Endocrinology, Diabetes & Metabolism $26,995.52
Nicholas Argento Laurel, MD Endocrinology, Diabetes & Metabolism $26,064.42
Kathleen Arnold Ocean Springs, MS Acute Care (Nurse Practitioner) $24,413.60
Lauren Sosdorf Zephyrhills, FL Nurse Practitioner $20,540.99
Kendra Butner Higginsville, MO Family $20,336.30
Thomas Blevins Austin, TX Endocrinology, Diabetes & Metabolism $20,247.21
Lowell Schmeltz Farmington Hills, MI Endocrinology, Diabetes & Metabolism $17,740.14
Robert Selfe Grand Rapids, MI Internal Medicine $17,343.59
Brenda Baxter Nashville, TN Adult Health (Nurse Practitioner) $16,639.20

Prescribed T:Slim X2 Insulin Pump With Control-Iq?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.